Try our beta test site

Raltegravir in the Swiss HIV Cohort Study

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2009 by University of Zurich.
Recruitment status was:  Recruiting
Swiss HIV Cohort Study
Merck Sharp & Dohme Corp.
Information provided by:
University of Zurich Identifier:
First received: May 18, 2009
Last updated: May 19, 2009
Last verified: May 2009

Since June 2007, raltegravir has been available in Switzerland within a named patient program for patients who have virologic failure, triple class experience and resistance, and no other treatment options. This proposal has been designed to evaluate efficacy and safety data among patients who receive raltegravir within the routine clinical practice in Switzerland and who participate in the Swiss HIV Cohort Study. This is a combined retrospective analysis of patients who already received raltegravir and a prospective part of patients who enter the named patient program and will be followed up in a standardized way. In the prospective part, patients will also be able to receive raltegravir in case of intolerance to their current medication with virologic suppression.

The analysis will primarily use descriptive statistics. In addition, we will assess the duration of virologic response and focus on predictors of HIV RNA suppression during a follow-up of at least 6 months. In the prospective part, we will assess trough plasma levels of raltegravir and other antiretrovirals. In patients who will develop virologic failure, genotypic and phenotypic resistance to raltegravir (and other antiretrovirals) will be performed to characterize the evolution of resistance during the raltegravir-containing regimen.

Condition Intervention
HIV Infection
Drug: Raltegravir

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Raltegravir Use in the Swiss HIV Cohort Study (SHCS) - Evaluation of Efficacy, Safety, Plasma Levels and Evolution of Resistance

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • HIV RNA < 50 copies/ml [ Time Frame: after 6 and 12 months ]

Secondary Outcome Measures:
  • durability of HIV RNA suppression [ Time Frame: time to virological failure ]
  • predictors of HIV RNA suppression (viral load and CD4 at baseline, resistance at baseline for those with detectable HIV RNA, number of active drugs within the salvage regimen [ Time Frame: baseline ]
  • time course of CD4 lymphocytes [ Time Frame: baseline until study end ]
  • severe drug-related adverse events [ Time Frame: during study period ]
  • drug levels of raltegravir and other antiretroviral drugs [ Time Frame: during first year of Ral treatment ]
  • evolution of resistance in patients with virologic failure while on raltegravir [ Time Frame: time to failure ]

Biospecimen Retention:   Samples With DNA
Within the framework of the Swiss HIV Cohort Study samples are taken of all patients regularly every 6 months. Plasma and frozen cells (

Estimated Enrollment: 200
Study Start Date: April 2008
Estimated Study Completion Date: April 2012
Estimated Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Salvage group
In this group patients are enrolled that have failed previous antiretroviral drug regimens and qualify for Raltegravir treatment according to the approved indication of this drug in Switzerland.
Drug: Raltegravir
Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
Other Name: Isentress
Switch group
In this group, patients are enrolled which have to switch to Raltegravir due to drug toxicity or adverse events caused by other antiretroviral drugs.
Drug: Raltegravir
Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
Other Name: Isentress


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The Swiss HIV Cohort study is a nationwide observational cohort existing for more than 20 years and is representative of the HIV-infected population in Switzerland (approx. 50% of HIV-infected patients in Switzerland, participate in this study). All patients must sign an informed consent to participate in this study.

The study population enrolled in the current "Raltegravir in the SHCS" study, is a subgroup of patients, that has to go on Raltegravir within the Swiss HIV Cohort study.


Inclusion Criteria:

  • all patients treated with Raltegravir within the Swiss HIV Cohort Study

Exclusion Criteria:

  • drop out of the Swiss HIV Cohort study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00904644

University Hospital Zurich
Zurich, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Swiss HIV Cohort Study
Merck Sharp & Dohme Corp.
Principal Investigator: Huldrych F Günthard, MD University of Zurich, University Hospital of Zurich, Switzerland
  More Information

Additional Information:
Responsible Party: Prof. Huldrych Günthard, MD, University of Zurich Identifier: NCT00904644     History of Changes
Other Study ID Numbers: SHCS Project No 564 
Study First Received: May 18, 2009
Last Updated: May 19, 2009

Keywords provided by University of Zurich:
antiretroviral treatment
Swiss HIV Cohort Study
drug resistance
integrase inhibitor

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Raltegravir Potassium
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
HIV Integrase Inhibitors
Integrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on February 17, 2017